Biotech Sector Turns Red-Hot on Alzheimer’s Treatment News 10.23.22 // Justin Spittler In Phase 3 trials, a Biogen / Eisai Alzheimer’s drug slowed cognitive decline by 27%.
Revisiting Freeport-McMoRan … and Bayer A year before writing about Freeport, I recommended readers buy shares of Bayer AG. Since pitching the idea, the stock is up 12.19%. And guess what? It's still cheap.
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million BMY will pay BBIO $90 million in upfront cash.
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement The companies are facing over 3,500 opioid-related lawsuits.
Bausch + Lomb Raises $630 Million in IPO, Missing Expectations The stock was priced at $18 per share, off a filing range of $21 - $24.
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.
Voyager Therapeutics Names Alfred Sandrock as CEO, Former Biogen R&D Head Sandrock spent 23 years at Biogen, where he was head of R&D and chief medical officer.
An Easy Way to Profit Off One of Today’s Strongest Sectors